Lion Point Capital »

Travere Therapeutics shares owned by Lion Point Capital

Quarter-by-quarter ownership of Travere Therapeutics (TVTX) shares owned by Lion Point Capital from 13F filings

Historical chart of Lion Point Capital investment in Travere Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Travere Therapeutics held by Lion Point Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Travere Therapeutics by Lion Point Capital

Quarter filed Position value Share count Share price at filing
2023-12-31 $701k 78k 8.99
2023-09-30 $697k 78k 8.94

More positions owned by Lion Point Capital

Semtech Corporation (SMTC)
Ishares Tr Russell 2000 Etf Put Option (IWM)
Marinus Pharmaceuticals Com New (MRNS)
Ardelyx (ARDX)
Milestone Pharmaceuticals (MIST)
Harpoon Therapeutics Com New
Burgerfi International (BFI)
Kiniksa Pharmaceuticals Com Cl A (KNSA)
Insmed Com Par $.01 (INSM)
Battalion Oil Corp (BATL)
Cymabay Therapeutics
Fennec Pharmaceuticals (FENC)
Avadel Pharmaceuticals Sponsored Adr (AVDL)
Enphys Acquisition Corp Cl A Ord Shs (NFYS)
Syndax Pharmaceuticals (SNDX)

View all positions for Lion Point Capital

Top funds holding Travere Therapeutics

Vanguard Group
Deutsche Bank Aktiengesellschaft
Kynam Capital Management
Jacobs Levy Equity Management
D. E. Shaw & Co
Bank of America Corporation
Goldman Sachs Group
Millennium Management
Emerald Advisers
Avidity Partners Management
Emerald Mutual Fund Advisers, Trust
Schonfeld Strategic Advisors
Barclays
Healthcare Of Ontario Pension Plan Trust Fund
Two Sigma Advisers

View all funds holding Travere Therapeutics